Bio-Rad Laboratories has climbed back into focus after a mixed share price record, and the key issue now is whether the ...

Bio-Rad Laboratories (BIO) drew fresh attention after CFO Roop K. Lakkaraju was slated for a fireside chat at the UBS Global ...

I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...

Bio-Rad has been challenged by tough end-market conditions in life sciences tools, but the outlook for 2025 is better. The company's cautious approach has led to lackluster sales growth and margin ...

The market didn't react positively to the diagnostics specialist's third-quarter earnings report. It beat on both the top and bottom lines, but growth rates were low.

Bio-Rad Laboratories is something of a rarity: a small-cap company with a wide economic moat. The company develops products and solutions for the clinical diagnostics and life sciences industries, ...